Stockholders' Equity - Summary of Warrants Outstanding (Details) - Warrants [Member] - $ / shares |
12 Months Ended | |
|---|---|---|
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Number of Warrants, Beginning Balance | 740,000 | 2,700,000 |
| Number of Warrants, Granted | 40,000 | |
| Number of Warrants, Exercised | ||
| Number of Warrants, Expired | (100,000) | (2,000,000) |
| Number of Warrants, Ending Balance | 640,000 | 740,000 |
| Weighted Average Exercise Price, Beginning Balance | $ 0.93 | $ 2.83 |
| Weighted Average Exercise Price, Granted | 1.00 | |
| Weighted Average Exercise Price, Exercised | ||
| Weighted Average Exercise Price, Expired | 1.00 | 3.50 |
| Weighted Average Exercise Price, Ending Balance | $ 1.00 | $ 0.93 |
| X | ||||||||||
- Definition Weighted average price at which non-option equity holders acquired shares when converting their non-option equity into shares. No definition available.
|
| X | ||||||||||
- Definition Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price. No definition available.
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. No definition available.
|
| X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|